Journal of Clinical Lipidology
Volume 2, Issue 4 , Pages 298-303 , August 2008

High levels of urinary F2-isoprostanes predict cardiovascular mortality in postmenopausal women

  • Mark Roest, PhD

      Affiliations

    • Research Laboratory of the Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, the Netherlands
    • ,
  • Hieronymus A.M. Voorbij, PhD

      Affiliations

    • Research Laboratory of the Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, the Netherlands
    • ,
  • Yvonne T. Van der Schouw, PhD

      Affiliations

    • The Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands
    • ,
  • Petra H.M. Peeters, PhD

      Affiliations

    • The Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands
    • ,
  • Tom Teerlink, PhD

      Affiliations

    • Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Peter G. Scheffer, PhD

      Affiliations

    • Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author.

Received 20 March 2008 ,Accepted 8 June 2008.

References 

  1. Okrainec K, Banerjee DK, Eisenberg MJ. Coronary artery disease in the developing world. Am Heart J. 2004;148:7–15
  2. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol. 2003;91:7A–11A
  3. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol. 2005;25:279–286
  4. Richelle M, Turini ME, Guidoux R, Tavazzi I, Metairon S, Fay LB. Urinary isoprostane excretion is not confounded by the lipid content of the diet. FEBS Lett. 1999;459:259–262
  5. Pratico D. F(2)-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis. 1999;147:1–10
  6. Yan W, Byrd GD, Ogden MW. Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS. J Lipid Res. 2007;48:1607–1617
  7. Reilly M, Delanty N, Lawson JA, FitzGerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 1996;94:19–25
  8. Davi G, Alessandrini P, Mezzetti A, et al. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1997;17:3230–3235
  9. Reilly MP, Pratico D, Delanty N, et al. Increased formation of distinct F-2 isoprostanes in hypercholesterolemia. Circulation. 1998;98:2822–2828
  10. Davi G, Gresele P, Violi F, et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo (Evidence derived from the study of peripheral arterial disease). Circulation. 1997;96:69–75
  11. Hirsch S, Ronco AM, Vasquez M, et al. Hyperhomocysteinemia in healthy young men and elderly men with normal serum folate concentration is not associated with poor vascular reactivity or oxidative stress. J Nutr. 2004;134:1832–1835
  12. Schwedhelm E, Bartling A, Lenzen H, et al. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation. 2004;109:843–848
  13. Monninkhof EM, Van der Schouw YT, Peeters PH. Early age at menopause and breast cancer: are leaner women more protected? (A prospective analysis of the Dutch DOM cohort). Breast Cancer Res Treat. 1999;55:285–291
  14. Roest M, Banga JD, Janssen WM, et al. Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation. 2001;103:3057–3061
  15. Bohnstedt KC, Karlberg B, Wahlund LO, Jonhagen ME, Basun H, Schmidt S. Determination of isoprostanes in urine samples from Alzheimer patients using porous graphitic carbon liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;796:11–19
  16. Gross M, Steffes M, Jacobs DR, et al. Plasma F2-isoprostanes and coronary artery calcification: the CARDIA Study. Clin Chem. 2005;51:125–131
  17. Keaney JF, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23:434–439
  18. Milne GL, Yin H, Brooks JD, Sanchez S, Jackson RL, Morrow JD. Quantification of f2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol. 2007;433:113–126
  19. Ohashi N, Yoshikawa M. Rapid and sensitive quantification of 8-isoprostaglandin F2alpha in human plasma and urine by liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Biomed Sci Appl. 2000;746:17–24
  20. Roberts LJ, Morrow JD. The generation and actions of isoprostanes. Biochim Biophys Acta. 1997;1345:121–135

PII: S1933-2874(08)00265-1

doi: 10.1016/j.jacl.2008.06.004

Journal of Clinical Lipidology
Volume 2, Issue 4 , Pages 298-303 , August 2008

Article Tools